期刊文献+

利塞膦酸盐抗男性骨质疏松性骨折的效应 被引量:2

Anti-fracture efficacy of risedronate in men with osteoporosis: a meta-analysis
下载PDF
导出
摘要 目的系统评价利塞膦酸盐对男性骨质疏松的抗骨折效应。方法通过Medline数据库、EMBASE数据库、Cochrane图书馆和中国生物医学文献数据库检索1980-01至2006-12有关利塞膦酸盐与安慰剂治疗男性骨质疏松患者的随机对照试验。随访大于12个月,提供骨折发生率的文献纳入研究。分析入选文献的方法学质量,提取资料,用RevMan4.2软件进行荟萃分析。结果3篇文献符合纳入标准,包括780例男性骨质疏松患者。荟萃分析结果显示利塞膦酸盐可降低69%的椎体骨折风险(RR=0.31,95%CI:0.16,0.60)和58%的非椎体骨折风险(RR=0.42,95%CI:0.23,0.78)。结论利塞膦酸盐对男性骨质疏松症患者可提供良好的抗骨折效应。 Objective To systematically assess the anti-fractuve efficacy of risedronate in men with osteoporosis. Methods Randomized controlled trials in men receiving risedronate or placebo for osteoporosis were searched from Medline, Embase, Cochrane Controlled Trial Registry and China Biological Medicine database between January, 1980 and December, 2005. We selected articles with a follow-up of at least 12 months and providing the incidence of fractures. The methodological quality of all eligible articles was independently assessed. Data from three trails were extracted and pooled. The analyses of the available data using the Revman 4.2 software were based on the intention-to-treat principle. Results Three trials, which included 780 men with primary or secondary osteoporosis, met all our inclusion criteria. The relative risk (RR) of vertebral and non-vertebral fractures were 0.31 [95% confidence intervals (CI) 0.16, 0.60] and 0.42[95% CI 0.23, 0.78] respectively. Compared with placebo, risedronate reduced the risk of vertebral fractures by 69% ( P = 0.0005) and the risk of non-vertebral fractures by 58% (P = 0.005 ). Conclusion Results of meta-analysis demonstrated that risedronate provides favorable antifracture efficacy in men with osteoporosis.
出处 《中国骨质疏松杂志》 CAS CSCD 2007年第9期659-662,共4页 Chinese Journal of Osteoporosis
关键词 利塞膦酸盐 骨质疏松 荟萃分析 骨折 男性 Risedronate Osteoporosis Meta-analysis Fracture Men
  • 相关文献

参考文献25

  • 1Cauley JA,Thompson DE,Ensrud KC,et al.Risk of mortality following clinical fractures.Osteoporos Int,2000,11:556-561.
  • 2Ross PD.Osteoporosis:frequency,consequences,and risk factors.Arch Intern Med,1996,156:1399-1411.
  • 3Campion JM,Maricic MJ.Osteoporosis in men.Am Fam Physician,2003,67:1521-1526.
  • 4Cooper C,Campion G,Melton LJ 3rd.Hip fractures in the elderly:a world-wide projection.Osteoporos Int,1992,2:285-289.
  • 5Center JR,Nguyen TV,Schneider D,et al.Mortality after all major types of osteoporotic fracture in men and women:an observational study.Lancet,1999,353:878-882.
  • 6Vestergaard P,Rejnmark L,Mosekilde L.Osteoporosis is markedlyunderdiagnosed:a nationwide study from Denmark.Osteoporos Int,2005,16:134-141.
  • 7Feldstein AC,Nichols G,Orwoll E,et al.The near absence of osteoporosis treatment in older men with fractures.Osteoporos Int,2005,16:953-962.
  • 8Sambrook P,Cooper C.Osteoporosis.Lancet,2006,367:2010-2018.
  • 9Palomha S,Orio F Jr,Manguso F,et al.Efficacy of risedronate administration in osteoporotic postmenopausal women affected by inflammatory bowel disease.Osteoporos Int,2005,16:1141-1149.
  • 10Kanis JA,Barton IP,Johnell O.Risedronate decreases fracture risk in patients selected solely on the basis of prior vertebral fracture.Osteoporos Int,2005,16:475-482.

同被引文献29

引证文献2

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部